In case anyone missed this:
April 6, 2020 11:37 AM ET (BZ Newswire)Teva Pharmaceutical Industries Ltd (NYSE:TEVA), which is beset by fundamental and legal woes, is entering a recovery phase, according to UBS Securities.
The Teva Analyst
Analyst Kevin Caliendo upgraded Teva from Neutral to Buy and lowered the price target from $14 to $12.